Related Experiment Videos
[Somatostatin and its receptors]
1Department of Metabolism and Clinical Nutrition, Kyoto University Faculty of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 1, 1996
Summary
Somatostatin (SST) analogs like SMS 201-995 show efficacy against endocrine tumors, potentially linked to somatostatin receptor 2 (SSTR2) expression. Further research into somatostatin receptors will aid in developing new diagnostic and therapeutic applications.
Area of Science:
- Molecular Endocrinology
- Oncology
- Neuroendocrinology
Context:
- Somatostatin-14 and somatostatin-28 are derived from prosomatostatin.
- Somatostatin receptors (SSTR1-5) form a family of structurally related proteins.
- These receptors exhibit distinct expression patterns, pharmacological profiles, and signaling pathways.
Purpose:
- To explore the relationship between somatostatin receptor expression and the efficacy of somatostatin analogs.
- To highlight the role of SSTR2 in the therapeutic response to SMS 201-995.
- To emphasize the potential of somatostatin receptor cloning in advancing tumor diagnosis and treatment.
Summary:
- Somatostatin analogs, such as SMS 201-995, are clinically used for endocrine tumors.
- Therapeutic efficacy appears correlated with the expression of somatostatin receptor 2 (SSTR2), which binds SMS 201-995 with high affinity.
- The somatostatin receptor family comprises five subtypes (SSTR1-5) with diverse characteristics.
Impact:
- Cloning somatostatin receptors can accelerate the development of novel somatostatin-based therapies.
- This research paves the way for improved diagnostic tools and targeted treatments for endocrine tumors.
- Understanding somatostatin receptor subtypes is crucial for personalized medicine in oncology.